Vendor Intelligence Report: Qingdao Saber Technology Pharma QST

Executive summary

Across 12 Finnrick lab tests, QST’s overall pass rate is 75%: 9 pass and 3 fail. That headline is not a total rejection and not a clean endorsement. The tested catalog is only Retatrutide and Tirzepatide; both sit in the same mixed band, with Tirzepatide marginally ahead on fewer observations and Retatrutide carrying the deeper record plus documented identity and fill-quality concerns. Ratings also fall under stricter grading, so QST’s profile is sensitive to methodology rather than resilient across scoring rules.

The operating footprint is real but accountability-light. QST shows a Premier Sponsor GLP-1 Forum presence, a Michelle King seller identity, Telegram/WhatsApp/Discord ordering routes, vendor COA posts and a claimed U.S. warehouse. The corporate trail is thinner: open registry and import-record checks did not verify the claimed Qingdao Saber Technology Pharma Co. Ltd entity, and qstpharma.com did not function as a buyer-verifiable official site during the investigation.

The central buyer issue is not whether QST has ever shipped usable material; Finnrick’s record includes passing lots. The issue is whether a buyer can tie a specific vial to a tested batch. QST posts Janoshik links, but the field run could not directly retrieve those pages, captured Finnrick rows repeatedly show unlabelled vials, and the reviewed materials did not document sterility or endotoxin testing for injectable products.

For a serious GLP-1 buyer, QST reads as a convenience-and-price channel that requires independent lot-level verification after receipt, not as a label-trust vendor. The full dossier is most useful for deciding whether a QST Retatrutide or Tirzepatide order is worth that extra verification burden.

Inside the full report:

• Captured Finnrick Retatrutide and Tirzepatide test tables showing identity-failure rows, batch identifiers, fill deviations and vial descriptions
• Per-product pass/fail rates, rating trajectories and methodology-divergence charts for both tested products
• Dated GLP-1 Forum timeline covering the Michelle King intro post, COA thread, warehouse announcements and dispute record
• Corporate and infrastructure checks across qstpharma.com, OpenCorporates, ImportYeti and login-walled Chinese registry leads
• COA-to-vial traceability analysis of QST’s posted Janoshik links, unlabelled vials and batch-matching gap
• Material buyer-risk matrix covering identity failures, fill consistency, sterility/endotoxin evidence and recourse opacity

Risk assessment

• Retatrutide/Tirzepatide identity and quality-failure risk — high: Current Finnrick record: Retatrutide 8 tests (6 pass / 2 fail, 78.19%) and Tirzepatide 4 tests (3 pass / 1 fail, 78.61%); captured rows show identity-failure language for both products.
• COA-to-vial traceability gap — high: Captured Finnrick rows repeatedly describe “No Label” vials; batch IDs appear late in the record and no evidence shows they are affixed to every vial, affecting all QST products.
• Retatrutide dose/fill consistency risk — medium: Retatrutide’s current rating is 78.19% across 8 tests, and captured Retatrutide rows show material fill variance; buyers should not assume label quantity without lot-level verification.
• Sterility and endotoxin evidence gap — medium: No QST forum post, COA thread entry, or promotional material in this run documented endotoxin or sterility testing for injectable products.
• Corporate and recourse opacity — medium: No OpenCorporates or ImportYeti match was found; qstpharma.com had no active site; sales route through Gmail, Telegram/WhatsApp and crypto, limiting buyer recourse.